TCTR20210317005已完成1 期
Effect of empagliflozin/linagliptin on albuminuria and urinary liver-type free fatty acid binding protein in type 2 diabetic patients with chronic kidney disease: A randomized controlled trial
/A0 个研究点目标入组 48 人开始时间: 2021年3月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Age more than 18 years
- •eGFR 30-59 ml/min/1.73m2
- •Stable glycemic treatment 3 months
- •No treatment adjusted with anti-HT within 1 month
排除标准
- •Sepsis/ any organ infection
- •Current history of urinary and genital tract infection
- •History of diabetic ketoacidosis
- •Pancreatic and active liver disease
- •Polycystic kidney disease
研究者
相似试验
已完成
4 期
EUROBEAT StudyType 2 diabetes mellitusJPRN-jRCTs051200147Makino Hisashi80
已完成
不适用
The effects of sitagliptin on albuminuria in patients with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000010871niversity of Occupational and Environmental Health100
进行中（未招募）
1 期
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients with Type 2 Diabetes Mellitus on Stable Metformin TreatmentType 2 Diabetes MellitusEUCTR2014-004895-48-DEProfil Institut für Stoffwechselforschung GmbH
尚未招募
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 10 mg Combined Linagliptin 5 mg Tablet formulations.IRCT20180620040164N69Cosar Pharmaceutical Co.24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 25 mg Combined Linagliptin 5 mg Tablet formulations.IRCT20180620040164N59Darou darman Pars Co.24